Table 6 Results of salvage therapy for pancreatic adenocarcinoma
From: Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
Ref | No. of pts | Treatment | m. age | PS 0 | M (%) | liver M (%) | >1CHT (%) | PPFS | ORR (%) | mPFS | PFS-6 (%) | 1 year OS (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 30 | I+E | 60 | 30 | 100 | 60 | 23 | Nr | 10 | 4.1 | Nr | 23 |
15a | 34 | G-FLIP | 64 | Nr | 100 | 85 | 29 | Nr | 24 | 3.9 | 20 | 20 |
17 | 17 | F+celecoxib | 60 | 35 | 82 | Nr | 0 | Nr | 35 | 1.9 | 6 | 20 |
21 | 18 | T | 59 | Nr | 100 | Nr | 22 | 7.9 | 5.5 | 3.3 | Nr | Nr |
26 | 15 | MDI | 61 | 26 | 100 | 60 | 20 | Nr | 0 | 1.7 | 0 | 0 |
29 | 33 | Ru | 62 | 0 | 73 | 57 | Nr | Nr | 9 | Nr | Nr | 6 |
30 | 19 | R | 60 | 21 | 100 | 74 | 0 | Nr | 0 | 2.5 | Nr | 0 |
30 | 19 | R+I | 63 | 21 | 100 | 63 | 0 | Nr | 16 | 4.0 | Nr | 22 |
cs | 41 | R+E | 61 | 61 | 100 | 80 | 15 | 6.0 | 24 | 1.8 | 15 | 12 |
